Search

Displaying results 4131 - 4140 of 4235 in total
  1. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

  2. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.

  3. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.

  4. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

  5. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.

  6. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  7. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  8. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  9. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

  10. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin and thereby preserving human immune cells by protecting against destruction of host cells mediated ...